Michelle Lujan Grisham actually said...
Unfortunately, it's not our first hearing on such matters. I mean, we are talking and dealing with Turing and Valeant and Mylan and Gilead, and seeing a really disturbing pattern where Congress provides a variety of mechanisms to invest in innovation and pharmaceutical companies so that we get the right public health treatments and medicines and that we also have innovations.
Context
Highlighting recurring issues with pharmaceutical companies and the need for innovation in public health.
09/20/2016